AGV04

AGV04 is a preclinical-stage small molecule therapeutic candidate being developed by AGV Discovery for the treatment of various cancers. AGV Discovery is a biotechnology company specializing in the field of epitranscriptomics, focusing on the discovery and development of small molecules that target RNA-modifying enzymes. These enzymes, such as RNA methyltransferases, play critical roles in regulating gene expression and are frequently dysregulated in oncological diseases. While AGV Discovery's lead programs (AGV01-03) are known to target the RNA methyltransferase METTL3, AGV04 is a distinct program targeting an undisclosed regulator within the same biological space. As of late 2021, the asset was positioned in the preclinical stage of development, though more recent updates on its specific status are limited.